Article

Practitioners see eye-to-eye when diagnosing, treating dry eye

Optometrists, general ophthalmologists, and cornea subspecialists have similar approaches to diagnosing and treating dry eye. Three clinician groups that relied on fluorescein staining and TFBUT for diagnosis found that cyclosporine emulsion 0.05% (Restasis, Allergan) was an important component of treatment for the majority of their eye-care practitioners.

Key Points

The three clinician groups surveyed reported that they relied on fluorescein staining and tear film break-up time (TFBUT) for diagnosis; ordering laboratory tests was relatively uncommon. Cyclosporine emulsion 0.05% (Restasis, Allergan) was an important component of treatment for the majority of eye care practitioners, with 60% to 70% of responding clinicians prescribing cyclosporine for patients with mild dry eye and 90% to 98% ordering cyclosporine for those with severe disease. Joseph Tauber, MD, and Scott Fudemberg, MD, conveyed the survey findings here at the annual meeting of the Association for Research in Vision and Ophthalmology.

Diagnostic measures

Considering the diagnostic measures used with patient A, corneal fluorescein staining was the most common choice among all responding clinician groups (about 90%) followed by measurement of TFBUT. About 60% of clinicians said they then would examine the eyelids for the degree of inflammation (meibomianitis or blepharitis) and eyelid closure. Schirmer's testing, the standard test for assessing dry eye disorders, would be performed less frequently than the other diagnostic tests.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.